Cardiovascular outcome evidence in diabetes and metabolism, including MACE, heart failure, renal outcomes, lipid therapy, hypertension, and cardiometabolic risk reduction.
A prespecified FLOW analysis found once-weekly semaglutide 1 mg lowered the risk of heart failure events or cardiovascular death in adults with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
Secondary analysis of the SELECT trial finds semaglutide 2.4 mg lowered all-cause death in adults with obesity and cardiovascular disease but no diabetes, with much of the non-cardiovascular benefit driven by fewer infectious and COVID-19-related deaths. PICO summary and expert commentary.
A prespecified SELECT analysis shows semaglutide reduced cardiovascular events in overweight or obese adults without diabetes regardless of baseline HbA1c or HbA1c change. PICO summary and expert commentary.
A secondary analysis of the SELECT trial examined whether weekly semaglutide 2.4 mg lowered all-cause, cardiovascular, non-cardiovascular, and COVID-19-related death in adults with overweight or obesity and cardiovascular disease without diabetes. PICO summary and expert commentary.
How patient and public involvement shaped the design of ASCEND PLUS, a decentralised RCT of oral semaglutide for cardiovascular prevention in type 2 diabetes. PICO summary and expert commentary.
A prespecified analysis of the SELECT trial shows once-weekly semaglutide produced a placebo-subtracted weight reduction of 10.2% sustained to 208 weeks in adults with cardiovascular disease and overweight or obesity but without diabetes. PICO summary and expert commentary.
A post-hoc pooled analysis of four semaglutide trials reports fewer worsening heart failure events in participants with HFpEF, with no significant effect on cardiovascular death. PICO summary and expert commentary.
A prespecified mortality analysis of the SELECT trial found that semaglutide 2.4 mg lowered all-cause death in adults with obesity and cardiovascular disease but no diabetes. PICO summary and expert commentary.
An echocardiography substudy of the STEP-HFpEF Program found that once-weekly semaglutide 2.4 mg attenuated adverse cardiac remodeling versus placebo over 52 weeks. PICO summary and expert commentary.
In adults with diabetes mellitus but no evident cardiovascular disease, aspirin at a dose of 100 mg daily significantly reduced the risk of serious vascular events by 12% compared to placebo, though it was associated with a 29% increased risk of major bleeding events.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
